Hester Biosciences Q1 FY27: standalone profit up 88%, consolidated surges on loan gain

Pat Growth 25pctExceptional ItemEbitda Margin ExpansionRevenue DeclineResults View source PDF Explain this filing

HESTERBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.5%Reaction day

₹2495.00

prior close

₹2490.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%+0.0% vs market

Pharmaceuticals peers, median of 162sector-0.8%+0.3% vs sector

On the reaction day the stock moved in line with Nifty Microcap 250 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+4.8

10m

+3.4

15m

+5.5

30m

+3.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.5-0.6+0.0-0.8+0.3

Next day

-1.7+0.5-2.2-0.5-1.2

-2.9+1.9-4.7+0.2-3.1

-0.6+2.3-2.9+0.1-0.7

-2.0+3.6-5.6+0.5-2.5

-1.0+4.0-5.0+0.7-1.7

+0.2+4.0-3.8+1.4-1.2

15d

-3.6+4.9-8.4+0.4-4.0

-9.6+5.9-15.5+1.7-11.3

-13.4+4.8-18.2+3.0-16.5

-7.5pendingpending-2.4-5.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Hester Biosciences posted Q1 FY27 standalone revenue of INR 726.6M, up 14% YoY. Standalone PAT rose 88% to INR 147.1M, EPS at INR 17.29. Poultry Healthcare grew 48%, Animal Healthcare fell 50% on government tender delays. Consolidated PAT jumped 459% to INR 967.3M, boosted by an exceptional INR 853.5M gain from Gates Foundation loan restructuring at Hester Africa.

Likely market impact

Strong Poultry growth and Gates loan gain boost profitability; Animal Healthcare and consolidated revenue remain soft.